STOCKHOLM, Sweden, Aug. 31, 2005 (PRIMEZONE) -- Artimplant raised 89 MSEK through an oversubscribed share issue. CE-mark of two new products within odontology and craniomaxillofacial surgery.
- Net revenue of 1.3 MSEK (1.0 MSEK)
- Net profit of --19.4 MSEK (-13.3 MSEK)
- Earnings per share of --0.39 SEK (-0.35 SEK)
- Artimplant raised 89 MSEK through an oversubscribed share issue
Events after the period
- Artimplant strengthened its commercial base through CE-mark of two new products within odontology and craniomaxillofacial surgery (surgery of cranial and facial bone tissue)
- Lars-Johan Cederbrant was employed as CFO
A full translation of the interim report is available at the company website.
ARTIMPLANT
Artimplant's mission is to develop novel biodegradable materials and implants that meet the needs of patients, physicians and healthcare providers in orthopedics and other therapy areas. The company works together with global partners as a center of excellence in this development.
Artimplant's vision is to become the partner of choice in biomaterials for hard and soft tissue repair in multiple therapy areas. Artimplant is a public company, listed on the Stockholm Exchange, O-list.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://wpy.waymaker.net/client/waymaker1/WOLReleaseFile.aspx?id=125967&fn=wkr0010.pdf